JP2021501169A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501169A5
JP2021501169A5 JP2020524039A JP2020524039A JP2021501169A5 JP 2021501169 A5 JP2021501169 A5 JP 2021501169A5 JP 2020524039 A JP2020524039 A JP 2020524039A JP 2020524039 A JP2020524039 A JP 2020524039A JP 2021501169 A5 JP2021501169 A5 JP 2021501169A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
subject
maintenance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501169A (ja
JP7315545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058039 external-priority patent/WO2019089473A1/en
Publication of JP2021501169A publication Critical patent/JP2021501169A/ja
Publication of JP2021501169A5 publication Critical patent/JP2021501169A5/ja
Priority to JP2023114146A priority Critical patent/JP7695298B2/ja
Application granted granted Critical
Publication of JP7315545B2 publication Critical patent/JP7315545B2/ja
Priority to JP2025093793A priority patent/JP2025131730A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524039A 2017-10-30 2018-10-29 Il-4r拮抗薬の投与により喘息を処置または予防するための方法 Active JP7315545B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023114146A JP7695298B2 (ja) 2017-10-30 2023-07-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2025093793A JP2025131730A (ja) 2017-10-30 2025-06-05 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762579120P 2017-10-30 2017-10-30
US62/579,120 2017-10-30
US201862710381P 2018-02-16 2018-02-16
US62/710,381 2018-02-16
US201862647368P 2018-03-23 2018-03-23
US62/647,368 2018-03-23
EP18305566 2018-05-04
EP18305566.4 2018-05-04
US201862742736P 2018-10-08 2018-10-08
US62/742,736 2018-10-08
PCT/US2018/058039 WO2019089473A1 (en) 2017-10-30 2018-10-29 Methods for treating or preventing asthma by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023114146A Division JP7695298B2 (ja) 2017-10-30 2023-07-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Publications (3)

Publication Number Publication Date
JP2021501169A JP2021501169A (ja) 2021-01-14
JP2021501169A5 true JP2021501169A5 (https=) 2021-12-02
JP7315545B2 JP7315545B2 (ja) 2023-07-26

Family

ID=64172607

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020524039A Active JP7315545B2 (ja) 2017-10-30 2018-10-29 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2023114146A Active JP7695298B2 (ja) 2017-10-30 2023-07-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2025093793A Pending JP2025131730A (ja) 2017-10-30 2025-06-05 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023114146A Active JP7695298B2 (ja) 2017-10-30 2023-07-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2025093793A Pending JP2025131730A (ja) 2017-10-30 2025-06-05 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Country Status (13)

Country Link
US (2) US11034768B2 (https=)
EP (2) EP3703818B1 (https=)
JP (3) JP7315545B2 (https=)
KR (3) KR102694419B1 (https=)
CN (1) CN111526920A (https=)
AU (2) AU2018359219B2 (https=)
CA (1) CA3079946A1 (https=)
ES (1) ES2969049T3 (https=)
HU (1) HUE064655T2 (https=)
IL (1) IL274134A (https=)
MX (2) MX2020004467A (https=)
PL (1) PL3703818T3 (https=)
WO (1) WO2019089473A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
HUE067888T2 (hu) * 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
WO2021243298A1 (en) * 2020-05-29 2021-12-02 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with an april binding antibody
JP2023544406A (ja) * 2020-10-05 2023-10-23 サノフィ・バイオテクノロジー Il-4rアンタゴニストを投与することによって小児対象における喘息を治療するための方法
US20250388685A1 (en) * 2024-04-15 2025-12-25 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2025240942A1 (en) * 2024-05-17 2025-11-20 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of eosinophilic copd
WO2025257810A1 (en) * 2024-06-14 2025-12-18 Singh Biotechnology, Llc Suppression of neurodegenerative diseases by single domain antibody

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH06510750A (ja) 1991-05-03 1994-12-01 セラジェン インク 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
ATE326239T1 (de) 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1304115B1 (en) 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60203652T2 (de) 2001-01-31 2005-09-08 Pfizer Products Inc., Groton Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyme
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
AR037456A1 (es) 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2004070011A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US20090062168A1 (en) 2007-08-27 2009-03-05 Joseph Timar Process for making a two-cycle gasoline engine lubricant
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
AU2009322556A1 (en) 2008-12-01 2011-07-21 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN107320722A (zh) 2009-09-07 2017-11-07 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
JP5167552B2 (ja) 2010-03-16 2013-03-21 エアソネット・アクチボラゲット 温度制御された層状空気流治療法による、喘息およびアレルギー性鼻炎の治療、ならびに睡眠の質の改善
EP3970726A1 (en) 2010-06-24 2022-03-23 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
UA111731C2 (uk) 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
EP2677838B1 (en) 2012-06-18 2017-12-06 Whirlpool Corporation Microwave heating apparatus
US9574004B2 (en) * 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CA3079946A1 (en) * 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) * 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
WO2021026205A1 (en) * 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Similar Documents

Publication Publication Date Title
JP2021501169A5 (https=)
Casale Biologics and biomarkers for asthma, urticaria, and nasal polyposis
Mukherjee et al. Anti-IL5 therapy for asthma and beyond
JP2017507139A5 (https=)
US9441037B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
JP2017535547A5 (https=)
JP2015527364A5 (https=)
RU2009140134A (ru) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
JP2016523863A5 (https=)
RU2016101632A (ru) Способы лечения полипоза носа путем введения антагониста il-4r
JP2017509692A5 (https=)
US20250034272A1 (en) Compositions and methods for treating severe asthma
US9441046B2 (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2016134838A (ru) Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком
JP2017507945A5 (https=)
JP2022530533A (ja) Il-33アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP2022541191A5 (https=)
Venegas Garrido et al. Airway autoimmunity, asthma exacerbations, and response to biologics
JP2021515039A5 (https=)
JP2025072440A5 (https=)
JP2025501239A5 (https=)
JP2023505215A5 (https=)
d’Ancona et al. Adherence to Inhaled Corticosteroids and Clinical Outcomes Following a Year of Tezepelumab Therapy for Severe Asthma